Drugs / 2X-121
2X-121
also known as
E7449 · 9X5A2QIA7C · CS-3479 · HY-12418 · MGI25036 · PARP INHIBITOR 2X-121 · PMID27841036-COMPOUND-37 · Stenoparib · +2 more
Small molecule targets PARP1, PARP2 via inhibition
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05571969 | Mar 2023 → Feb 2024 | cancer | Allarity Therapeutics | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06681220 | Feb 2026 → Dec 2029 expected | small cell lung carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02396433 | Apr 2015 | breast cancer | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01618136 | Jan 2012 → Jul 2015 | indolent B-cell non-Hodgkin lymphoma, melanoma, ovarian carcinoma, triple-negative breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03878849 | Apr 2019 → Mar 2027 expected | ovarian cancer | Allarity Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT03562832 | Jun 2018 → Apr 2024 | breast cancer | Allarity Therapeutics | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2X-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05571969 ↗ |
| Known as | 9X5A2QIA7C | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | CS-3479 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | E7449 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01618136 ↗ |
| Known as | HY-12418 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | MGI25036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | PARP INHIBITOR 2X-121 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | PMID27841036-COMPOUND-37 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | Stenoparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06681220 ↗ |
| Known as | STENOPARIB (E7449) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | UNII-9X5A2QIA7C | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Action | Inhibit | “E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor.” PMID 32523090 ↗ Jun 20202“Poly [ADP-ribose] polymerase 2 inhibitor” CHEMBL3644587 ↗ “Poly [ADP-ribose] polymerase-1 inhibitor” CHEMBL3644587 ↗ |
| Modality | Small molecule | “2X-121 is a small molecule targeted inhibitor” NCT03562832 ↗ |
| Route | Oral | “E7449 will be administered as single agent orally, once daily (QD) continuously in 28-day cycles” NCT01618136 ↗ |
| Target | PARP1 | “Poly [ADP-ribose] polymerase-1 inhibitor” CHEMBL3644587 ↗ |
| Target | PARP2 | “Poly [ADP-ribose] polymerase 2 inhibitor” CHEMBL3644587 ↗ |